Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Marion E. Morrison"'
Autor:
Odin Naderer, Allen Melemed, Randall Lanier, Marion E. Morrison, Jyotsna Fuloria, Tom Brundage, Joseph A. Lasky
Publikováno v:
Advances in Therapy
Introduction: The COVID-19 Global Pandemic caused by the novel coronavirus, SARS-CoV-2, and the consequent morbidity and mortality attributable to progressive hypoxemia and subsequent respiratory failure, threaten to overrun hospital critical care un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33780a782c89d7679bf8de8c961be976
Autor:
Marion E. Morrison, Allen Melemed, Jyotsna Fuloria, Randall Lanier, Joseph A. Lasky, Tom Brundage, Odin Naderer
Background: The COVID-19 Global Pandemic caused by the novel coronavirus, SARS-CoV-2, and the consequent morbidity and mortality attributable to progressive hypoxemia and subsequent respiratory failure, threaten to overrun hospital critical care unit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c88440dceda6e261d0d70cf5e8a8365
https://doi.org/10.21203/rs.3.rs-52289/v1
https://doi.org/10.21203/rs.3.rs-52289/v1
Autor:
Thangam Arumugham, Marion E. Morrison, Odin Naderer, Maggie Anderson, Virna Schuck, John Dale Dunn
Publikováno v:
Open Forum Infectious Diseases
Background BCV is a lipid conjugated nucleotide analog that has shown rapid viral clearance with oral administration in patients with adenovirus infection, and improved survival in animal models of smallpox. Phase I single ascending dose evaluation o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06e659406cac485980edf8ad538bcc3f
https://doi.org/10.1093/ofid/ofy210.1252
https://doi.org/10.1093/ofid/ofy210.1252
Publikováno v:
Antiviral research. 143
Brincidofovir (BCV, CMX001) is an orally available, long-acting, broad-spectrum antiviral that has been evaluated in healthy subjects in Phase I studies and in hematopoietic cell transplant recipients and other immunocompromised patients in Phase II/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63ff6329f9567c5a05b0e2fdcc8c07c9
https://pubmed.ncbi.nlm.nih.gov/28093339
https://pubmed.ncbi.nlm.nih.gov/28093339
Publikováno v:
Therapeutic Drug Monitoring
Supplemental Digital Content is Available in the Text.
Background: Brincidofovir (BCV) is an orally bioavailable lipid conjugate of cidofovir (CDV) with increased in vitro potency relative to CDV against all 5 families of double-stranded DNA vir
Background: Brincidofovir (BCV) is an orally bioavailable lipid conjugate of cidofovir (CDV) with increased in vitro potency relative to CDV against all 5 families of double-stranded DNA vir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff60501b5c42cec775399b454fffc02f
https://pubmed.ncbi.nlm.nih.gov/27851688
https://pubmed.ncbi.nlm.nih.gov/27851688
Autor:
Roy F. Chemaly, Janet A. Englund, Gregory E. Chittick, Marion E. Morrison, Andrew Bae, Joanne Kurtzberg, Vinod K. Prasad, Michael Grimley, Thomas M. Brundage
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 23(3)
Adenovirus infection in immunocompromised patients contributes to significant morbidity and mortality, especially after allogeneic hematopoietic cell transplantation (HCT). Brincidofovir (BCV, CMX001) is an orally bioavailable lipid conjugate of cido
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a9633df68ef854f77e06d30f3ba946d
https://pubmed.ncbi.nlm.nih.gov/28063938
https://pubmed.ncbi.nlm.nih.gov/28063938
Autor:
Herve Mommeja-Marin, Francisco M. Marty, Kathlene M. Mullane, Genovefa A. Papanicolaou, Drew J. Winston, Michael Boeckh, Thomas M. Brundage, Tsiporah B. Shore, Roy F. Chemaly, Marion E. Morrison
Publikováno v:
Biology of Blood and Marrow Transplantation. 22(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36a998eacca2defe4871173084a915cf
Autor:
Mary Beth Wire, Odin Naderer, Thangam Arumugham, John Dale Dunn, Marion E. Morrison, Maggie Anderson
Publikováno v:
Open Forum Infectious Diseases
Background BCV is a lipid conjugate nucleotide that has shown rapid viral clearance in patients with adenovirus infection and improved survival in animal models of smallpox. In preclinical studies in rats, IV BCV dosed twice weekly for up to 29 days
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c2e28c394aeaae21a96218e35824d95
http://europepmc.org/articles/PMC5631843
http://europepmc.org/articles/PMC5631843